KIAA0087: A Non-coding RNA Molecule as A Drug Target and Biomarker

Target Name: KIAA0087

NCBI ID: G9808

KIAA0087

Other Name(s): KIAA0087 lncRNA

KIAA0087: A Non-coding RNA Molecule as A Drug Target and Biomarker

KIAA0087 (KIAA0087 long non-coding RNA) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the TGF-β pathway, a well-known signaling pathway that plays a crucial role in cell growth, differentiation, and repair.

The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. The pathway is composed of several transcription factors, including SMAD, KLF1, and TGF-β1. These transcription factors bind to specific DNA sequences to regulate the expression of genes that are involved in cell growth and differentiation.

KIAA0087 is a non-coding RNA molecule that is known to interact with the TGF-β1 transcription factor. It is a critical regulator of the TGF-β pathway, and it is involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

One of the key functions of KIAA0087 is to regulate the activity of the TGF-β1 transcription factor. This transcription factor is involved in the regulation of cellular processes such as cell growth, differentiation, and survival, and it is a key factor in the development and maintenance of tissues and organs.

KIAA0087 is also involved in the regulation of the apoptosis (programmed cell death) process. Apoptosis is a natural process that is involved in the regulation of cellular life and death, and it is a key factor in the development and maintenance of tissues and organs.

In addition to its functions in regulating the TGF-β pathway and apoptosis, KIAA0087 is also involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. These processes are important for the development and maintenance of tissues and organs, and they are regulated by a complex interplay of transcription factors and other signaling molecules.

The potential drug target status of KIAA0087 is supported by several studies. For example, experiments have shown that KIAA0087 can be expressed and translated into proteins in cancer cells, and that it can interact with the TGF-β1 transcription factor. These findings suggest that KIAA0087 may be a potential drug target for cancer.

In addition to its potential as a drug target, KIAA0087 is also a potential biomarker for several diseases. For example, KIAA0087 has been shown to be downregulated in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. These findings suggest that KIAA0087 may be a potential biomarker for these diseases.

In conclusion, KIAA0087 is a non-coding RNA molecule that is involved in the regulation of the TGF-β pathway and apoptosis. It is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the functions of KIAA0087 and its potential as a drug and biomarker.

Protein Name: KIAA0087 LncRNA

The "KIAA0087 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIAA0087 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets